NAVIFY® Tumor Board 2.0

eHealthNews.nz: Covid-19

Monday, 20 April 2020

Share |

Empowering oncology teams with virtual multidisciplinary team meetings

In light of the on-going global pandemic COVID-19, we at Roche are aware how important it is to take an agile approach to maintaining health services. People with certain types of cancer are among those groups of patients at higher risk of coronavirus complications. As such, Roche wishes to offer our support by providing oncology multidisciplinary teams (MDT) 6+ months access to NAVIFY® Tumor Board at no charge to help with remote and asynchronous ways of working.

Cancer MDTs may need to seek new ways of working whilst maintaining standards of care in the patient pathway and reporting on clinical outcomes and operational targets. Chairing, attending and managing MDT meetings will become increasingly challenging: there will be insufficient attendance for MDT meetings and a lack of accessible information.

How NAVIFY® Tumor Board can help?

Consolidate, securely share and display clinical and patient information for an MDT meeting, including remote Pathologist presentation capabilities.
Enable and support clinical decision making, assign specific follow up actions, track decisions and record next steps.
Clinical information can be securely viewed and managed from any location via a web browser.
Staff can simultaneously (or asynchronously) collaborate and prepare and discuss patient cases.

Who NAVIFY® Tumor Board can help?

All cancer services who provide MDT meetings for solid tumours

Rapid onboarding

Cloud-based solution: no hardware prerequisites or installation.
Accessible from anywhere there is internet access through Google Chrome and IE11.
Flexible training options including: in app training, short videos and quick reference cards.
Remote support on-demand via a dedicated implementation manager.
Supports integration with web-conferencing solutions.

Security

NAVIFY® Tumor Board is designed to operate in accordance with the laws and regulations including APP (Australia), IPP (New Zealand), GDPR (UK), HIPPA (US)
NAVIFY® Tumor Board has obtained ISO-27001, ISO-27017 and ISO-2018 certification

Next steps

We would welcome the opportunity to discuss proceeding with this. For more information please contact our Digital Business Representatives: Ben Robinson (ben.robinson@roche.com) or Roberto Tsukazan (roberto.tsukazan@roche.com).

For further information on our product visit http://www.navify.com.

Source: Roche Diagnostics Australia Pty. Ltd. media release, 20 April 2020

Sector updates are provided by organisations to eHealthNews.nz and have not necessarily been edited or checked for accuracy. Any queries should be directed to the organisation issuing the release.

For more information and resources about COVID-19 go to https://www.hinz.org.nz/page/covid19

Do you have an item to add to sector updates?

Email your information to us at updates@hinz.org.nz

Return to eHealthNews.nz home page